Showing results (1251-1260 of 1,650) with videos related to
Sort By:
Pageof 165
Therapeutic Innovation & Regulatory Science|December 5, 2024
Efficient Positioning of QTL and Secondary Limit Thresholds in a Clinical Trial Risk-Based MonitoringVladimir ShnaydmanTherapeutic Innovation & Regulatory Science|November 29, 2024
Research on Core Competency Elements of Clinical InvestigatorsXin Wang, Shuang Zhao, Han Yang, et al.Therapeutic Innovation & Regulatory Science|November 21, 2024
Comparison of Borrowing Methods for Incorporating Historical Data in Single-Arm Phase II Clinical TrialsSara Urru, Michela Verbeni, Danila Azzolina, et al.Therapeutic Innovation & Regulatory Science|February 21, 2025
Catering the Need of Drug Manufacturing Standard in India: An Update to Indian PharmacopoeiaBikash Kumar Sah, Faiz Ahmad, Ankit Kumar, et al.Therapeutic Innovation & Regulatory Science|February 23, 2025
Sponsor- vs. FDA-Initiated Changes to Pediatric Clinical Trial Protocols: A Comparison of Associated Participant BurdenSusan Abdel-Rahman, Zoe Sund, Cheryl Alderman, et al.Therapeutic Innovation & Regulatory Science|November 17, 2025
Nitrosamine Contamination in Pharmaceuticals: A Retrospective Regulatory Analysis of USFDA Recalls and Risk Mitigation Strategies (2018-2025)Sravani Yerram, V P Muhammad Nizam, Saurabh Srivastava, et al.Therapeutic Innovation & Regulatory Science|December 28, 2020
Has the COVID-19 Crisis Affected the Growth of United States Food and Drug Administration Drug Approvals? The Answer is Not Yet! A Time Series (Forecasting) StudyIraj DaizadehTherapeutic Innovation & Regulatory Science|December 10, 2022
Why are There not More Bayesian Clinical Trials? Ability to Interpret Bayesian and Conventional Statistics Among Medical Researchers, Ross Bray, Andrew Hartley, et al.Therapeutic Innovation & Regulatory Science|October 1, 2020
Unicorn Poo and Blessed Waters: COVID-19 Quackery and FDA Warning LettersKatrina A BramstedtTherapeutic Innovation & Regulatory Science|August 29, 2020
Impact of Real-World Data on Market Authorization, Reimbursement Decision & Price NegotiationAlfredo Aram Pulini, Gabriela Martins Caetano, Henri Clautiaux, et al.Pageof 165